The phase III INTORSECT trial failed to demonstrate superiority in PFS for the mTOR inhibitor temsirolimus over the VEGF inhibitor sorafenib as treatment for patients with renal cell carcinoma in the second-line setting. As a result, in this segment, panelists discuss this trial and its implications on sequencing.

To view more from this discussion, visit [ Ссылка ]

свернуть